In case the p values were smaller than 0.05, differences were considered to be statistically significant. All data were obtained from at least two independent experiments using at least two independent individuals. The authors are grateful to Dr. Junji Takeda and Dr. Jun-ichi Miyazaki for providing Cre-expressing mice. The authors also thank Dr. Toshio Imai, Dr. Chikako Nishigori, and Dr. Yoichi Kurebayashi for helpful discussions, and Dr. Mingzhen Li, Dr. Yunfeng Bai, Dr. Shuzo Ikuta, Ms. Keiko Sumimoto, and Mr. Kazuhiro Takegawa for suggestions. This work was supported by Grants-in-Aid

to T. K. (1701406, 20390080, Global COE Program A08) and to H. E. (20790229, 22790290) from the Ministry selleck inhibitor of Education, Culture, Sports, Science and Technology of Japan, a Grant for the Program for Promotion of Fundamental Studies of Health Sciences 06-3 from the National Institute of Biomedical Innovation to T. K., a grant from Kanae Foundation for the Promotion of Medical Science to H. E., and a buy Adriamycin Grant-in-Aid for Japan Society for the Promotion

of Science Fellows 19-55411 to N. T. Conflict of interest: The authors declare no financial or commercial conflict of interest. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. “
“Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a major negative regulatory molecule for T-cell activation with a complex biology and function. CTLA-4 is known to regulate homeostatic lymphoproliferation as well as tolerance induction and has been proposed to be an important effector molecule by which Treg cells suppress immunity. The immunoregulatory properties of CTLA-4 are primarily mediated by competition with the costimulator

CD28 for ligand binding but also by delivering negative signals to T cells through its cytoplasmic tail. In this study, we addressed the effect of directly mutating the amino acid residue, Tyrosine 201 (Tyr201), of the intracellular domain of CTLA-4 in situ and its implications in T-cell function in the context of autoimmunity. Therefore, a novel CTLA-4 knock-in mouse (Y201V KI) was generated, in which Tyr201 was replaced by a valine Temsirolimus in vitro that could not be phosphorylated. Mice expressing the CTLA-4 mutant molecule were generally healthy and did not show signs of disruption of T-cell homeostasis under steady-state conditions seen in CTLA-4 deficient mice. However, T cells isolated from Y201V KI mice expressed higher levels of CTLA-4 on the cell surface and displayed a Th2-biased phenotype following TCR stimulation. Furthermore, Y201V KI mice developed exacerbated disease as compared to wild-type upon antigen-specific T-cell activation in an in vivo model of EAE. Importantly, the Y201V mutation resulted in impaired suppressive activity of Treg cells while T effector function remained intact.